Next Article in Journal
High Risk of Sustained Ventricular Arrhythmia Recurrence After Acute Myocarditis
Previous Article in Journal
Ischemia-Reperfusion Injury in Marginal Liver Grafts and the Role of Hypothermic Machine Perfusion: Molecular Mechanisms and Clinical Implications
Open AccessArticle

Five Years Outcomes and Predictors of Events in a Single-Center Cohort of Patients Treated with Bioresorbable Coronary Vascular Scaffolds

1
Kardiologie I, Zentrum für Kardiologie, University Medical Center Mainz and Deutsches Zentrum für Herz und Kreislauf Forschung, Standort Rhein-Main 55131 Mainz, Germany
2
Division of Cardiology, Department of Medical and Surgical Sciences, "Magna Graecia" University, 88100 Catanzaro, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(3), 847; https://doi.org/10.3390/jcm9030847
Received: 2 January 2020 / Revised: 14 March 2020 / Accepted: 16 March 2020 / Published: 20 March 2020
(This article belongs to the Section Cardiology)
Introduction: We report outcome data of patients treated with coronary bioresorbable scaffolds up to 5 years and investigate predictors of adverse events. Methods: Consecutive patients treated with at least one coronary bioresorbable scaffold (BRS, Abbott Vascular, Santa Clara, USA) between May 2012 and May 2014 in our center were enrolled. Clinical/procedural characteristics and outcome data at 1868 (1641–2024) days were collected. The incidence of scaffold thrombosis (ScT), restenosis (ScR), and target lesion failure (TLF) and their predictors were investigated using Kaplan–Meier and Cox regression analysis. Results: 512 consecutive patients and 598 lesions were included in the database. A total of 30 ScT, 42 ScR, and 92 TLF were reported. The rate of ScT was 3.6% in the first year, 2.2% in the second–third year, and 0.6% in the fourth–fifth year after implantation. The corresponding rates of ScR were 2.5%, 5.7%, and 1.1%. The corresponding incidence of TLF was 8.8%, 8.0%, 3.8%. Procedural parameters (vessel size, scaffold footprint) and the technique used at implantation (including predilation, parameters of sizing, and postdilation) were predictors of ScT and TLF in the first three years after implantation. In contrast, only diabetes was predictive of events between 4–5 years (HR 6.21(1.99–19.40), p = 0.002). Conclusions: After device resorption, the incidence of very late adverse events in lesions/patients implanted with a BRS decreases. Procedural and device-related parameters are not predictors of events anymore. View Full-Text
Keywords: restenosis; thrombosis; bioresorbable scaffolds; coronary stent restenosis; thrombosis; bioresorbable scaffolds; coronary stent
Show Figures

Figure 1

MDPI and ACS Style

Anadol, R.; Mühlenhaus, A.; Trieb, A.-K.; Polimeni, A.; Münzel, T.; Gori, T. Five Years Outcomes and Predictors of Events in a Single-Center Cohort of Patients Treated with Bioresorbable Coronary Vascular Scaffolds. J. Clin. Med. 2020, 9, 847.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop